Mariner, LLC Vaxart, Inc. Transaction History

Mariner, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$0.69 - $0.85 $7,011 - $8,637	10,162 New	10,162 $7,000
Q4 2022 Feb 14, 2023	BUY	$0.75 - $2.24 $255 - $763	341 Added 0.15%	231,204 $222,000
Q3 2022 Nov 10, 2022	SELL	$2.09 - $4.5 $22,388 - $48,204	-10,712 Reduced 4.43%	230,863 $503,000
Q2 2022 Aug 15, 2022	SELL	$2.7 - $5.28 $24,786 - $48,470	-9,180 Reduced 3.66%	241,575 $846,000
Q1 2022 May 13, 2022	BUY	$4.29 - $6.64 $430,471 - $666,277	100,343 Added 66.71%	250,755 $1.26 Million
Q4 2021 Feb 14, 2022	BUY	$5.77 - $7.96 $969 - $1,337	168 Added 0.11%	150,412 $943,000
Q3 2021 Nov 15, 2021	BUY	$6.67 - $9.8 $206 - $303	31 Added 0.02%	150,244 $1.19 Million
Q2 2021 Aug 24, 2021	BUY	$5.06 - $10.78 $1,077 - $2,296	213 Added 0.14%	150,213 $1.13 Million
Q1 2021 May 07, 2021	BUY	$5.64 - $23.33 $225,081 - $931,053	39,908 Added 36.25%	150,000 $908,000
Q4 2020 Feb 16, 2021	BUY	$3.5 - $7.98 $385,322 - $878,534	110,092 New	110,092 $629,000

107

37.7M

188K

180K

Ticker VXRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 126,506,000
Market Cap $86M
Description
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1...

Get notified when there are updates to the investment portfolio of Mariner, LLC, based on Form 13F filings with the SEC.

Stay updated on Mariner, LLC with notifications on news.